Related Experiment Video
Updated: Oct 13, 2025
Cell Labeling and Targeting with Superparamagnetic Iron Oxide Nanoparticles
Published on: October 19, 2015
Surface specifically modified NK-92 cells with CD56 antibody conjugated superparamagnetic Fe3O4 nanoparticles for
Songbo Zhao1, Jiazhi Duan2, Yalin Lou1
1Key Laboratory for Experimental Teratology of Ministry of Education, Shandong Key Laboratory of Infection and Immunity, and Department of Immunology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, 250012, P. R. China. glfflg@sdu.edu.cn.
Abstract:
Although there has been significant progress in the development of tumor immunotherapies, many challenges still exist for the treatment of solid tumors. Natural killer (NK) cells possess broad-spectrum cytotoxicity against tumors, but their limited migration and infiltration abilities restrict their application in solid tumor therapies. Here, we combined a facile and efficient magnetic-targeting strategy with NK cell-based therapy to develop a novel immunotherapy approach for treating solid tumors. Anti-CD56 antibodies were conjugated with Fe3O4 nanoparticles, which could specifically bind with NK-92 cells endowing them with a magnetic field driven targeting ability. These NK-Fe3O4 biohybrid nanoparticles were able to facilitate directional migration to the tumor site in vivo under external magnetic field guidance and efficiently inhibit tumor growth. These functionalized NK cells represent a novel approach for solid tumor therapy and may provide a promising modality for cancer interventions in the future.
Insights
Researchers developed magnetic nanoparticles to guide Natural Killer (NK) cells to solid tumors. This novel immunotherapy approach enhances NK cell targeting and inhibits tumor growth, offering a promising cancer intervention.
Area of Science:
- Immunology
- Nanotechnology
- Oncology
Background:
- Solid tumor immunotherapy faces challenges, particularly with Natural Killer (NK) cell migration and infiltration.
- Existing immunotherapies have limitations in effectively targeting solid tumors.
Purpose of the Study:
- To develop a novel immunotherapy approach for solid tumors by enhancing NK cell targeting capabilities.
- To overcome the limitations of NK cell migration and infiltration in solid tumor treatment.
Main Methods:
- Conjugation of anti-CD56 antibodies with Fe3O4 nanoparticles to create NK-Fe3O4 biohybrid nanoparticles.
- Utilizing an external magnetic field to guide the migration of functionalized NK cells to tumor sites in vivo.
- Assessing the efficacy of the NK-Fe3O4 biohybrid nanoparticles in inhibiting tumor growth.
Main Results:
- The NK-Fe3O4 biohybrid nanoparticles demonstrated specific binding to NK-92 cells, imparting magnetic targeting ability.
- The functionalized NK cells showed directional migration to tumor sites under magnetic field guidance.
- Significant inhibition of solid tumor growth was observed using this novel approach.
Conclusions:
- The magnetic-targeting strategy combined with NK cell therapy offers a promising new approach for solid tumor treatment.
- Functionalized NK cells can overcome migration limitations, enhancing their therapeutic potential against solid tumors.
- This strategy represents a novel modality for future cancer interventions.
